An interventional study of Sterile solutions of recombinant human nerve growth factor (NGF) in Nerve Growth Factor, Exercise and Motor Activity, sponsored by Aalborg University. Completed at 1 site in Denmark. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-03-05.
Sponsored by Aalborg University · Not applicable, Interventional, and Basic science
Among 17 studies in Hyperalgesia with a site in Denmark — none open to participants now, none under way, none of them phase 3. Hyperalgesia · Denmark.
Among the 17 studies in Hyperalgesia with a site in Denmark, this one is the 7th largest by enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2017, is one of 6 with no phase, and was the 15th registered.
166 studies on the registry are indexed under Hyperalgesia; 14 are open to participants now.
Browse Hyperalgesia studies →None of the 17 studies in Hyperalgesia with a site in Denmark is open now.
Of the 8 Hyperalgesia studies recruiting now, 4 (50%) set no upper age limit and 2 (25%) stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 3 started in 2017.
This study's enrollment of 24 is below the median of 50 across 142 interventional studies indexed under Hyperalgesia.
Median enrollment 23 across the 15 interventional studies, 32 across the 2 observational. Of the 16 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 17 has an industry lead sponsor. The 5 most frequent:
Aalborg University is the lead sponsor of 182 studies on the registry; 31 are open to participants now.
Aalborg University has 5 studies filed under Hyperalgesia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 17 studies in Hyperalgesia with a site in Denmark, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate the sensory-motor cortical excitability response to delayed onset muscle soreness (DOMS) on Extensor Carpi Radialis (ECR) muscle during muscle hyperalgesia provoked by nerve growth factor (NGF).
The purpose of this study is to assess changes in sensory-motor cortical excitability during experimental muscle hyperalgesia across several days provoked by injections of nerve growth factor (NGF) into the Extensor Carpi Radialis (ECR) muscle and delayed onset muscle soreness (DOMS) of the ECR muscle.
It was hypothesized that muscle hyperalgesia across several days would result in:
i) Increased sensory cortical excitability, based on somatosensory evoked potentials by means of electrical stimulation of the radial nerve, (increase of central-parietal evoked-potential P45 and decrease of frontal evoked-potential N30); ii) Increased corticomotor excitability of a ECR (increase map volume and number of active sites), assessed as motor evoked potentials induced by transcranial magnetic stimulation in primary motor cortex (M1); iii) Reduction of alpha oscillation based on nociceptive stimulus-evoked suppression of alpha activity in sensory regions (recording electrodes on contra-lateral parietal area);
166 studies on the registry are indexed under Hyperalgesia; 14 are open to participants now.
This study's enrollment of 24 is below the median of 50 across 142 interventional studies indexed under Hyperalgesia.
Browse Hyperalgesia studies →Aalborg University is the lead sponsor of 182 studies on the registry; 31 are open to participants now.
Compared within Hyperalgesia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Motor Activity. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Inclusion Criteria:
Exclusion Criteria:Pregnancy
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Three injections of sterile solutions of recombinant human nerve growth factor (NGF) will be performed in the right extensor carpi radialis muscle to induce muscle hyperalgesia.
Drug: Sterile solutions of recombinant human nerve growth factor (NGF)
Injections of nerve growth factor and eccentric exercise of the extensor carpi radialis muscle will be performed to induce muscle hyperalgesia.
Drug: Sterile solutions of recombinant human nerve growth factor (NGF)
The intramuscular injections of NGF cause muscle soreness.
Pain rating
Pain on an 11-point numerical rating scale (0 = no pain, 10 = most intense pain imaginable)
Time frame: Change from baseline at 2 weeks
Muscle soreness
7-point Likert scale; 0 = 'a complete absence of soreness', 1 = 'a light soreness in the muscle felt only when touched/vague ache', 2 = 'a moderate soreness felt only when touched/a slight persistent ache', '3 = 'a light muscle soreness when lifting or carrying objects', 4 = 'a light muscle soreness, stiffness or weakness when moving the wrist without gripping an object', 5 = 'a moderate muscle soreness, stiffness or weakness when moving the wrist', 6 = 'a severe muscle soreness, stiffness or weakness that limits the ability to move'
Time frame: Change from baseline at 2 weeks
Patient-rated Tennis Elbow Evaluation
The Patient-rated Tennis Elbow Evaluation will be used to assess average pain and disability of the injected arm
Time frame: Change from baseline at 2 weeks
Pressure pain thresholds
Pressure applied to the surface of the skin using a handheld algometer.
Time frame: Change from baseline at 2 weeks
Motor evoked potentials
Transcranial magnetic stimualtion will be used to evoke motor evoked potentials (MEPs) to the extensor carpi radialis muscle
Time frame: Change from baseline at 1 week
Sensory evoked potentials
EEG recodring
Time frame: Change from baseline at 1 week
Alpha oscillations
Continuous EEG recording
Time frame: Change from baseline at 1 weeks
Ran from Nov 2017 to primary completion in Feb 2018, 3 months.
Of 27 non-industry interventional studies with no phase under Hyperalgesia, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 32. This study's 3 months is below that.
Counting every sponsor, half of 27 studies reached it within 11 months; a quarter within 4 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nerve Growth Factor